Cancer Biomarkers Market

Cancer Biomarkers Market by Type (Protein, Genetic), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnostics, R&D, Prognostics), Region - Global Forecast to 2026

Report Code: MD 5627 Mar, 2022, by marketsandmarkets.com

[287 Pages Report] The global cancer biomarkers market is projected to reach USD 28.2 billion by 2026 from USD 12.4 billion in 2021, at a CAGR of 17.7%. Market growth is driven by the increasing use of cancer biomarkers in drug discovery and development, increasing research on cancer biomarkers, technological advancements, and the increasing global incidence of cancer.

Cancer Biomarkers Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on Global Cancer Biomarkers Market

It was originally thought novel coronavirus (covid-19, sars-cov-2) was primarily a respiratory disorder, but as larger numbers of patients contracted the virus, it quickly became clear it had many physiological manifestations. The impact of covid-19 goes well beyond the lungs to impact the cardiovascular system and cause complications in the kidneys, brain, and other organs. Critical patients often require care from a multidisciplinary care team. Furthermore, COVID patients with comorbidities were more likely to have severe symptoms requiring hospitalization. Still, patients with pre-existing cardiovascular diseases suffer the highest mortality rate of all COVID patients.

In some cases, COVID causes acute heart failure, myocarditis, shock, and thromboembolism, and the drugs being used to treat the virus can compound cardiac issues by causing arrhythmias. However, there has been a greater than 50% drop in the number of patients presenting to cardiology and those diagnosed with myocardial infarction. All areas of cardiology service provision sustained significant reductions, including outpatient clinics, investigations, procedures, and cardiology community services such as heart failure and cardiac rehabilitation.

The implications of decreased testing are of great concern for many stakeholders, including physicians, hospitals, laboratories, pharmaceutical companies, and, most importantly, patients. Diagnosis and cancer biomarker testing is the earliest indicators of treatment, which can include new targeted therapies with the potential to improve patient results; they should not be delayed. Routine screening for breast, ovarian and colorectal cancer also needs to be done timely as they constitute effective preventive and early detection measures. The pandemic has significantly and negatively altered how cancer patients are being diagnosed and treated in the near term.

Market Dynamics

Driver: Rising technological advancements In the development of cancer biomarkers

The advancements in arrays and proteomics technologies have addressed the challenges in identifying and understanding the functions and interactions of various proteins. These technological advancements have simplified the process of discovery & development of novel cancer biomarkers to a great extent.

Opportunity: Personalized medicine

Personalized medicine identifies the most beneficial treatment path for individual patients. Cancer biomarkers play a very important role in certain aspects of personalized medicine. Consumables used in cancer biomarker testing enable the identification of these diseases. Cancer biomarker diagnostic products are also used as companion diagnostics for several investigational therapies. Thus, the field of personalized medicine is expected to offer potential growth opportunities for players operating in the cancer biomarkers market.

Restraint: Technical issues related to sample collection and storage

sample collection is one of the key issues for service providers, followed by access to these samples. Stringent quality control of these samples is required, and they need to be stored under the right conditions to avoid any loss. Also, different samples are required for risk detection, screening, diagnosis, and monitoring processes.

Challenge: Challenges associated with cancer biomarker validation

The cancer biomarker validation process includes evaluating assays or measuring performance characteristics such as sensitivity, specificity, and reproducibility. Validation is critical for establishing cancer biomarkers as reliable tools to support development, medical care, and biopharma investment decisions.

In 2020, protein biomarkers segment accounted for the largest share of the cancer biomarkers market, by biomarkers type

The cancer biomarkers market is segmented into protein biomarkers, genetic biomarkers and other cancer biomarkers based on biomarkers type. The protein biomarkers segment accounted for the largest share of the cancer biomarkers market in 2020, mainly due to the increasing research on cancer biomarkers.

 “In 2020, breast cancer segment accounted for the largest share of the cancer biomarkers market, by cancer type”

The cancer biomarkers market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, thyroid cancer, bladder cancer, non-hodgkin's lymphoma, kidney cancer and other cancer types based on cancer type. In 2020, the breast cancer segment accounted for the largest share. Factors such as increasing incidence of cancer worldwide drives the growth.

In 2020, omics technologies segment accounted for the largest share in the cancer biomarkers market, by profiling technologies

The cancer biomarkers market has been segmented into omics technologies, imaging technologies, immunoassay, bioinformatics and cytogenetics. In 2020, the omics technologies segment accounted for the largest share of the cancer biomarkers market. Increase use of cancer biomarkers for new developments is driving the growth of this segment.

In 2020, diagnostics segment accounted for the largest share in the cancer biomarkers market, by application

The cancer biomarkers market has been segmented into diagnostics, research & development, prognostics, risk assessment and other applications. In 2020, the diagnostics segment accounted for the largest share of the cancer biomarkers market. Increase in application of cancer biomarkers for companion diagnostics will drive the market growth.

North America is the largest regional market for cancer biomarkers market

The global cancer biomarkers market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the global cancer biomarkers market. The North American cancer biomarkers market's growth can be attributed to the correlation between increasing population and increased research activities.

Cancer Biomarkers Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Some key players in the cancer biomarkers market (2021- 2026)

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2019–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD)

Segments covered

Biomarkers type, cancer type, profiling technologies, application and region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Companies covered

F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMιrieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), Quest Diagnostics (US), Centogene N.V. (Germany), PerkinElmer, Inc.      (US), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems, Inc. (US), BioVision, Inc. (US), Olink (Sweden), Asuragen, Inc. (US), Meso Scale Diagnostics, LLC (US), Invivoscribe, Inc. (US), Seegene Technologies, Inc. (South Korea).

This report categorizes the cancer biomarkers market into the following segments and subsegments:

By Biomarkers Type

  • Protein Biomarkers
  • Genetic Biomarkers
  • Other Cancer Biomarkers

By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma
  • Leukemia
  • Thyroid Cancer
  • Bladder Cancer
  • Non-Hodgkin's Lymphoma
  • Kidney Cancer
  • Other Cancer Types

By Profiling Technologies

  • Omics Technologies
  • Imaging Technologies
  • Immunoassay
  • Bioinformatics
  • Cytogenetics

By Application

  • Diagnostics
  • Research & Development
  • Prognostics
  • Risk Assessment
  • Other Applications

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia and New Zealand
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

Recent Developments

  • In April 2021, F. Hoffmann-La Roche Ltd. (Switzerland), Launched Elecsys Anti-p53 immunoassay to aid the diagnosis of various cancer types.
  • In December 2020, Thermo Fisher Scientific (US) received FDA approves NGS-based companion diagnostic for EGFR Exon20 insertion mutant non-small cell lung cancer tumor tissue.
  • In April 2020, Qiagen N.V. (Netherlands) Launched therascreen BRAF test as a companion diagnostic to a BRAFTOVI (encorafenib) based regimen in metastatic colorectal cancer.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 35)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
           1.2.2 MARKETS COVERED
                    FIGURE 1 CANCER BIOMARKERS MARKET SEGMENTATION
           1.2.3 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
    1.4 LIMITATIONS
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 41)
    2.1 RESEARCH DATA
    2.2 RESEARCH APPROACH
           FIGURE 2 CANCER BIOMARKERS MARKET: RESEARCH DESIGN
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Primary sources
                    2.2.2.2 Key data from primary sources
                    2.2.2.3 Key industry insights
                    2.2.2.4 Breakdown of primary interviews
                               FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
                               FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION
           2.3.1 BOTTOM-UP APPROACH
                    2.3.1.1 Approach 1: Company revenue estimation approach
                               FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
                    2.3.1.2 Approach 2: Presentations of companies and primary interviews
                    2.3.1.3 Growth forecast
                    2.3.1.4 CAGR projections
                               FIGURE 6 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
                    FIGURE 7 CANCER BIOMARKERS MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN & DATA TRIANGULATION
           FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE
    2.6 ASSUMPTIONS FOR THE STUDY
    2.7 LIMITATIONS
    2.8 RISK ASSESSMENT
           2.8.1 RISK ASSESSMENT: CANCER BIOMARKERS MARKET
    2.9 GROWTH RATE ASSUMPTIONS
    2.10 COVID-19 HEALTH ASSESSMENT
    2.11 COVID-19 ECONOMIC ASSESSMENT
    2.12 ASSESSMENT OF IMPACT OF COVID-19 ON ECONOMIC SCENARIO
           FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
           FIGURE 10 RECOVERY SCENARIO OF GLOBAL ECONOMY
    2.13 ASSESSMENT OF IMPACT OF COVID-19 ON CANCER BIOMARKERS MARKET

3 EXECUTIVE SUMMARY (Page No. - 58)
    FIGURE 11 CANCER BIOMARKERS MARKET, BY BIOMARKERS TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 12 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 13 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    FIGURE 14 CANCER BIOMARKERS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
    FIGURE 15 CANCER BIOMARKERS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 62)
    4.1 CANCER BIOMARKERS MARKET OVERVIEW
           FIGURE 16 RISING TECHNOLOGICAL ADVANCEMENTS FOR THE DEVELOPMENT OF CANCER BIOMARKERS TO DRIVE MARKET GROWTH
    4.2 CANCER BIOMARKERS MARKET SHARE, BY BIOMARKER TYPE, 2021 VS. 2026
           FIGURE 17 THE PROTEIN BIOMARKERS SEGMENT IS EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
    4.3 CANCER BIOMARKERS MARKET SHARE, BY CANCER TYPE, 2021 VS. 2026
           FIGURE 18 LUNG CANCER SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
    4.4 CANCER BIOMARKERS MARKET SHARE, BY PROFILING TECHNOLOGY, 2021 VS. 2026
           FIGURE 19 THE OMICS TECHNOLOGIES SEGMENT IS EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
    4.5 CANCER BIOMARKERS MARKET SHARE, BY APPLICATION, 2021 VS. 2026
           FIGURE 20 HOSPITALS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
    4.6 CANCER BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 21 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 66)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 22 CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising technological advancements in the development of cancer biomarkers
                    5.2.1.2 Increasing incidence of cancer worldwide
                               TABLE 1 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
                               TABLE 2 PROJECTED INCREASE IN THE GLOBAL NUMBER OF CANCER PATIENTS, 2015─2O35
                    5.2.1.3 Increasing use of cancer biomarkers in drug discovery & development
                    5.2.1.4 Increasing R&D on cancer biomarkers
           5.2.2 RESTRAINTS
                    5.2.2.1 Technical issues related to sample collection and storage
                    5.2.2.2 High capital investments and extensive timelines for the development of cancer biomarkers
                               TABLE 3 TIMEFRAME FOR THE DEVELOPMENT OF BIOMARKERS
                    5.2.2.3 Unfavorable regulatory and reimbursement scenario
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increased recognition of personalized medicine
                               FIGURE 23 PERCENTAGE OF CANCER CLINICAL TRIALS INCORPORATING CANCER BIOMARKERS
                    5.2.3.2 Growing application areas of companion diagnostics
                    5.2.3.3 Emerging economies
           5.2.4 CHALLENGES
                    5.2.4.1 Challenges associated with cancer biomarker validation
                    5.2.4.2 Shortage of skilled professionals
    5.3 IMPACT OF COVID-19 ON CANCER BIOMARKERS MARKET
    5.4 PESSIMISTIC, OPTIMISTIC, AND REALISTIC SCENARIOS
           5.4.1 CANCER BIOMARKERS MARKET
                    FIGURE 24 PESSIMISTIC SCENARIO
                    FIGURE 25 OPTIMISTIC SCENARIO
                    FIGURE 26 REALISTIC SCENARIO
    5.5 PRICING ANALYSIS
           TABLE 4 PRICE OF CANCER BIOMARKERS BY PRODUCT & SERVICE (2021)
    5.6 PATENT ANALYSIS
           5.6.1 PATENT ANALYSIS OF THE CANCER BIOMARKERS MARKET
    5.7 TRADE ANALYSIS
           5.7.1 TRADE ANALYSIS FOR MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS
                    TABLE 5 IMPORT DATA FOR MRI SYSTEMS, BY COUNTRY, 2016–2020 (USD MILLION)
                    TABLE 6 EXPORT DATA FOR MRI SYSTEMS, BY COUNTRY, 2016–2020 (USD MILLION)
    5.8 VALUE CHAIN ANALYSIS
           FIGURE 27 MAJOR VALUE IS ADDED DURING MANUFACTURING & ASSEMBLY PHASE
    5.9 SUPPLY CHAIN ANALYSIS
           FIGURE 28 CANCER BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS
    5.10 ECOSYSTEM ANALYSIS OF CANCER BIOMARKERS MARKET
           FIGURE 29 CANCER BIOMARKERS MARKET: ECOSYSTEM ANALYSIS
           5.10.1 ROLE IN ECOSYSTEM
    5.11 PORTER’S FIVE FORCES ANALYSIS
           TABLE 7 CANCER BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.11.1 THREAT OF NEW ENTRANTS
           5.11.2 THREAT OF SUBSTITUTES:
           5.11.3 BARGAINING POWER OF BUYERS
           5.11.4 BARGAINING POWER OF SUPPLIERS
           5.11.5 DEGREE OF COMPETITION
    5.12 REGULATORY ANALYSIS
           5.12.1 INTRODUCTION
           5.12.2 CANCER BIOMARKERS QUALIFICATION IN THE US
           5.12.3 CANCER BIOMARKERS QUALIFICATION IN THE EU
           5.12.4 CANCER BIOMARKERS ACCEPTANCE IN DRUG DEVELOPMENT IN THE EU AND THE US
           5.12.5 METHOD: EMA APPROVALS
           5.12.6 METHOD: FDA APPROVALS
    5.13 TECHNOLOGY ANALYSIS
    5.14 PESTLE ANALYSIS
    5.15 TRENDS/DISRUPTIONS IMPACTING THE BUSINESS OF CUSTOMERS
           5.15.1 REVENUE SOURCES ARE SHIFTING TOWARDS TECHNOLOGY-BASED SOLUTIONS DUE TO THE COVID-19 PANDEMIC
           FIGURE 30 YC-YCC SHIFT FOR CANCER BIOMARKERS MARKET

6 CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE (Page No. - 93)
    6.1 INTRODUCTION
           TABLE 8 CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
           TABLE 9 CANCER BIOMARKERS MARKET FOR BIOMARKERS TYPE, BY REGION, 2020–2026 (USD MILLION)
    6.2 PROTEIN BIOMARKERS
           6.2.1 INCREASED EFFORTS OF PHARMACEUTICAL COMPANIES TO DISCOVER PROTEIN BIOMARKERS FOR EARLY STAGES TO DRIVE MARKET GROWTH
                    TABLE 10 CANCER BIOMARKERS MARKET FOR PROTEIN BIOMARKERS, BY REGION, 2020–2026 (USD MILLION)
    6.3 GENETIC BIOMARKERS
           6.3.1 ADVANCEMENTS IN HIGH-THROUGHPUT TECHNOLOGIES TO DRIVE MARKET GROWTH
                    TABLE 11 CANCER BIOMARKERS MARKET FOR GENETIC BIOMARKERS, BY TYPE, 2020–2026 (USD MILLION)
                    TABLE 12 CANCER BIOMARKERS MARKET FOR GENETIC BIOMARKERS, BY REGION, 2020–2026 (USD MILLION)
           6.3.2 LUNG CANCER
           6.3.3 BREAST CANCER
           6.3.4 PROSTATE CANCER
           6.3.5 LEUKEMIA
           6.3.6 OTHER CANCERS
    6.4 OTHER CANCER BIOMARKERS
           TABLE 13 CANCER BIOMARKERS MARKET FOR OTHER CANCER BIOMARKERS, BY REGION, 2020–2026 (USD MILLION)

7 CANCER BIOMARKERS MARKET, BY CANCER TYPE (Page No. - 103)
    7.1 INTRODUCTION
           TABLE 14 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
           TABLE 15 CANCER BIOMARKERS MARKET FOR CANCER TYPE, BY REGION, 2020–2026 (USD MILLION)
    7.2 BREAST CANCER
           7.2.1 AVAILABILITY & UTILISATION OF ADVANCED TECHNOLOGIES BY MAJOR PLAYERS IN BREAST CANCER DETECTION TO DRIVE MARKET GROWTH
                    TABLE 16 BREAST CANCER INCIDENCE, BY REGION, 2020 VS 2040
                    TABLE 17 CANCER BIOMARKERS MARKET FOR BREAST CANCER, BY REGION, 2020–2026 (USD MILLION)
    7.3 LUNG CANCER
           7.3.1 INCREASING FOCUS ON LUNG CANCER BIOMARKERS DEVELOPMENT TO DRIVE MARKET GROWTH
                    TABLE 18 LUNG CANCER INCIDENCE, BY REGION, 2020 VS 2040
                    TABLE 19 CANCER BIOMARKERS MARKET FOR LUNG CANCER, BY REGION, 2020–2026 (USD MILLION)
    7.4 COLORECTAL CANCER (CRC)
           7.4.1 RISING DEMAND FOR BIOMARKERS IN THE EARLY DIAGNOSIS & PROGNOSIS OF CRC TO DRIVE THE MARKET GROWTH
                    TABLE 20 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS 2040
                    TABLE 21 CANCER BIOMARKERS MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2026 (USD MILLION)
    7.5 PROSTATE CANCER
           7.5.1 ADVANCEMENTS IN GENOMIC TECHNOLOGIES ARE ENABLING THE DEVELOPMENT OF NEW BIOMARKERS FOR PROSTATE CANCER
                    TABLE 22 CANCER BIOMARKERS MARKET FOR PROSTATE CANCER, BY REGION, 2020–2026 (USD MILLION)
    7.6 MELANOMA
           7.6.1 INCREASING UTILIZATION OF DIAGNOSTICS IN BRAF INHIBITOR THERAPY TO DRIVE THE MARKET GROWTH
                    TABLE 23 MELANOMA INCIDENCE, BY REGION, 2020 VS 2040
                    TABLE 24 CANCER BIOMARKERS MARKET FOR MELANOMA, BY REGION, 2020–2026 (USD MILLION)
    7.7 LEUKEMIA
           7.7.1 RESEARCH STUDIES FOR THE DEVELOPMENT OF ACCURATE DIAGNOSTIC METHODS IN LEUKEMIA TO DRIVE MARKET GROWTH
                    TABLE 25 CANCER BIOMARKERS MARKET FOR LEUKEMIA, BY REGION, 2020–2026 (USD MILLION)
    7.8 THYROID CANCER
           7.8.1 RESEARCH UNDERTAKEN FOR THE IDENTIFICATION OF NEW BIOMARKERS FOR THYROID NODULES TO DRIVE THE MARKET GROWTH
                    TABLE 26 CANCER BIOMARKERS MARKET FOR THYROID CANCER, BY REGION, 2020–2026 (USD MILLION)
    7.9 BLADDER CANCER
           7.9.1 APPROVAL OF SEVERAL URINARY BIOMARKERS FOR THE DETECTION OF BLADDER CANCER TO SUPPORT THE SEGMENT GROWTH
                    TABLE 27 CANCER BIOMARKERS MARKET FOR BLADDER CANCER, BY REGION, 2020–2026 (USD MILLION)
    7.10 NON-HODGKIN’S LYMPHOMA (NHL)
           7.10.1 INCREASING RESEARCH ACTIVITIES ON NHL TO DRIVE THE MARKET GROWTH
                    TABLE 28 CANCER BIOMARKERS MARKET FOR NON-HODGKIN’S LYMPHOMA, BY REGION, 2020–2026 (USD MILLION)
    7.11 KIDNEY CANCER
           7.11.1 DEVELOPMENT OF SEVERAL NEW TARGETED THERAPIES FOR THE TREATMENT OF KIDNEY CANCER TO DRIVE THE MARKET GROWTH
                    TABLE 29 CANCER BIOMARKERS MARKET FOR KIDNEY CANCER, BY REGION, 2020–2026 (USD MILLION)
    7.12 OTHER CANCERS
           TABLE 30 CANCER BIOMARKERS MARKET FOR OTHER CANCERS, BY REGION, 2020–2026 (USD MILLION)

8 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY (Page No. - 118)
    8.1 INTRODUCTION
           TABLE 31 CANCER BIOMARKERS MARKET FOR PROFILING TECHNOLOGY, BY TYPE, 2020–2026 (USD MILLION)
           TABLE 32 CANCER BIOMARKERS MARKET FOR PROFILING TECHNOLOGY, BY REGION, 2020–2026 (USD MILLION)
    8.2 OMICS TECHNOLOGY
           8.2.1 INCREASING DEMAND FOR ADVANCED OMICS TECHNOLOGIES TO DRIVE MARKET GROWTH
                    TABLE 33 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGY, BY TYPE, 2020–2026 (USD MILLION)
                    TABLE 34 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGY, BY REGION, 2020–2026 (USD MILLION)
           8.2.2 PROTEOMICS
                    8.2.2.1 Increasing discovery rate of protein biomarkers and the rising need for rapid and cost-efficient diagnostic tests to drive segment growth
                               TABLE 35 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2020–2026 (USD MILLION)
           8.2.3 GENOMICS
                    8.2.3.1 The rising potential of genomics technologies in the development of biomarkers for disease prediction
                               TABLE 36 CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2020–2026 (USD MILLION)
                               TABLE 37 CANCER BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2020–2026 (USD MILLION)
                    8.2.3.2 NEXT-GENERATION SEQUENCING (NGS)
                               8.2.3.2.1 Introducing advanced NGS platforms by leading players to increase productivity to drive the growth of this segment
           TABLE 38 CANCER BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2020–2026 (USD MILLION)
                    8.2.3.3 POLYMERASE CHAIN REACTION (PCR)
                               8.2.3.3.1 Cost-effectiveness and the easy availability of PCR tests to propel the growth of this segment
                                            TABLE 39 CANCER BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2020–2026 (USD MILLION)
           8.2.4 OTHER OMICS TECHNOLOGIES
                    TABLE 40 CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY REGION, 2020–2026 (USD MILLION)
    8.3 IMAGING TECHNOLOGIES
           8.3.1 THE USE OF IMAGING BIOMARKERS IN DRUG DISCOVERY & DEVELOPMENT PROCESSES TO DRIVE THE GROWTH OF THIS MARKET
                    TABLE 41 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2020–2026 (USD MILLION)
                    TABLE 42 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2020–2026 (USD MILLION)
           8.3.2 ULTRASOUND IMAGING
                    8.3.2.1 Use of ultrasound for biomarker research in the understanding of disease onset & progression to drive the growth of this segment
                               TABLE 43 CANCER BIOMARKERS MARKET FOR ULTRASOUND IMAGING, BY REGION, 2020–2026 (USD MILLION)
           8.3.3 COMPUTED TOMOGRAPHY (CT)
                    8.3.3.1 The adoption of CT in cancer biomarker discovery is increasing rapidly
                               TABLE 44 CANCER BIOMARKERS MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2020–2026 (USD MILLION)
           8.3.4 MAGNETIC RESONANCE IMAGING (MRI)
                    8.3.4.1 MRI use in differentiating normal and diseased tissues to pinpoint cancerous cells precisely supports the growth of this segment
                               TABLE 45 CANCER BIOMARKERS MARKET FOR MAGNETIC RESONANCE IMAGING, BY REGION, 2020–2026 (USD MILLION)
           8.3.5 POSITRON EMISSION TOMOGRAPHY (PET)
                    8.3.5.1 Development of lab-on-chip-based multiplex assays to support the market growth
           TABLE 46 CANCER BIOMARKERS MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY REGION, 2020–2026 (USD MILLION)
           8.3.6 MAMMOGRAPHY
                    8.3.6.1 Advanced technologies like 3D mammography to drive the growth of this segment
                               TABLE 47 CANCER BIOMARKERS MARKET FOR MAMMOGRAPHY, BY REGION, 2020–2026 (USD MILLION)
    8.4 IMMUNOASSAYS
           8.4.1 THE INCREASING PREVALENCE OF BREAST CANCER IS A KEY FACTOR DRIVING THE GROWTH OF THIS SEGMENT
                    TABLE 48 CANCER BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION, 2020–2026 (USD MILLION)
    8.5 BIOINFORMATICS
           8.5.1 RISING TECHNOLOGICAL ADVANCEMENTS AND THE GROWING INFORMATION TECHNOLOGY SECTOR TO DRIVE MARKET GROWTH
                    TABLE 49 CANCER BIOMARKERS MARKET FOR BIOINFORMATICS, BY REGION, 2020–2026 (USD MILLION)
    8.6 CYTOGENETICS
           8.6.1 CYTOGENETICS ARE GENETICS-BASED TESTS THAT ARE RELIABLE IN THE QUANTITATIVE & QUALITATIVE EVALUATION OF BIOMARKERS
                    TABLE 50 CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY TYPE, 2020–2026 A(USD MILLION)
                    TABLE 51 CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY REGION, 2020–2026 (USD MILLION)
           8.6.2 IN-SITU HYBRIDIZATION (ISH)
                    8.6.2.1 Use of ISH-based diagnostic tests help identify specific biomarkers in clinical trials
                               TABLE 52 CANCER BIOMARKERS MARKET FOR IN-SITU HYBRIDIZATION, BY REGION, 2020–2026 (USD MILLION)
           8.6.3 OTHER CYTOGENETICS-BASED TESTS
                    TABLE 53 CANCER BIOMARKERS MARKET FOR OTHER CYTOGENETICS-BASED TESTS, BY REGION, 2020–2026 (USD MILLION)

9 CANCER BIOMARKERS MARKET, BY APPLICATION (Page No. - 140)
    9.1 INTRODUCTION
           TABLE 54 CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
           TABLE 55 CANCER BIOMARKERS MARKET FOR APPLICATION, BY REGION, 2020–2026 (USD MILLION)
    9.2 DIAGNOSTICS
           9.2.1 INCREASED AWARENESS & ACCEPTANCE OF TECHNOLOGICALLY ADVANCED BIOMARKER PRODUCTS TO DRIVE MARKET GROWTH
                    TABLE 56 CANCER BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION, 2020–2026 (USD MILLION)
    9.3 RESEARCH & DEVELOPMENT
           9.3.1 INCREASING FOCUS OF PHARMACEUTICAL COMPANIES ON BIOMARKERS USE IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET GROWTH
                    TABLE 57 CANCER BIOMARKERS MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2020–2026 (USD MILLION)
    9.4 PROGNOSTICS
           9.4.1 GROWING ADOPTION OF SPECIFIC AND SENSITIVE BIOMARKER TESTS TO DRIVE MARKET GROWTH
                    TABLE 58 CANCER BIOMARKERS MARKET FOR PROGNOSTICS, BY REGION, 2020–2026 (USD MILLION)
    9.5 RISK ASSESSMENT
           9.5.1 RISK ASSESSMENT BIOMARKERS TO INCREASE CANCER CLINICAL TRIALS FOR DRUG DEVELOPMENT
                    TABLE 59 CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT, BY REGION, 2020–2026 (USD MILLION)
    9.6 OTHER APPLICATIONS
           TABLE 60 CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2026 (USD MILLION)

10 CANCER BIOMARKERS MARKET, BY REGION (Page No. - 147)
     10.1 INTRODUCTION
             TABLE 61 CANCER BIOMARKERS MARKET, BY REGION, 2020–2026 (USD MILLION)
     10.2 NORTH AMERICA
             TABLE 62 NUMBER OF NEW CANCER CASES IN NORTH AMERICA IN 2020, BY CANCER TYPE
             FIGURE 31 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035
             FIGURE 32 NORTH AMERICA: CANCER BIOMARKERS MARKET SNAPSHOT
             TABLE 63 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
             TABLE 64 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
             TABLE 65 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
             TABLE 66 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
             TABLE 67 NORTH AMERICA: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
             TABLE 68 NORTH AMERICA: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
             TABLE 69 NORTH AMERICA: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
             TABLE 70 NORTH AMERICA: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION)
             TABLE 71 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
                        10.2.1.1 Increasing use of cancer biomarkers for cancer treatment drives the market growth
                                     TABLE 72 KEY GROWTH STRATEGIES BY LEADING PLAYER FOR THE DEVELOPMENT OF CANCER BIOMARKERS
                                     TABLE 73 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                     TABLE 74 US: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 75 US: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 76 US: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
                                     TABLE 77 US: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 78 US: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 79 US: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 80 US: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 81 US: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Increasing government initiatives for the discovery & development of cancer biomarkers to drive the market growth
                                     TABLE 82 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                     TABLE 83 CANADA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 84 CANADA: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 85 CANADA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
                                     TABLE 86 CANADA: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 87 CANADA: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 88 CANADA: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 89 CANADA: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 90 CANADA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
     10.3 EUROPE
             FIGURE 33 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035
             TABLE 91 EUROPE: CANCER BIOMARKERS MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
             TABLE 92 EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
             TABLE 93 EUROPE: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
             TABLE 94 EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY , 2020–2026 (USD MILLION)
             TABLE 95 EUROPE: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
             TABLE 96 EUROPE: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
             TABLE 97 EUROPE: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
             TABLE 98 EUROPE: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION)
             TABLE 99 EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Favorable government health policies to drive the market growth for cancer biomarkers in Germany
                                     TABLE 100 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                     TABLE 101 GERMANY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 102 GERMANY: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 103 GERMANY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
                                     TABLE 104 GERMANY: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 105 GERMANY: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 106 GERMANY: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 107 GERMANY: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 108 GERMANY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 Availability of government funding and strategic collaborations with biotech firms have significantly boosted the adoption of biomarkers in the UK
                                     TABLE 109 UK: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                     TABLE 110 UK: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 111 UK: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 112 UK: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY , 2020–2026 (USD MILLION)
                                     TABLE 113 UK: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 114 UK: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 115 UK: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 116 UK: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 117 UK: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Increasing government investments in genomics & proteomics research to drive the market growth in France
                                     TABLE 118 FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                     TABLE 119 FRANCE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 120 FRANCE: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 121 FRANCE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
                                     TABLE 122 FRANCE: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 123 FRANCE: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 124 FRANCE: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 125 FRANCE: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 126 FRANCE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 Increasing research activities on the discovery for novel cancer biomarkers using tissue diagnostic techniques to drive the market growth
                                     TABLE 127 ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                     TABLE 128 ITALY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 129 ITALY: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 130 ITALY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
                                     TABLE 131 ITALY: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 132 ITALY: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 133 ITALY: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 134 ITALY: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 135 ITALY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Increasing focus on personalized medicine to drive the market growth for cancer biomarkers in Spain
                                     TABLE 136 SPAIN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                     TABLE 137 SPAIN: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 138 SPAIN: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 139 SPAIN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
                                     TABLE 140 SPAIN: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 141 SPAIN: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 142 SPAIN: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 143 SPAIN: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 144 SPAIN: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
             10.3.6 REST OF EUROPE
                        TABLE 145 ROE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
                        TABLE 146 ROE: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
                        TABLE 147 ROE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
                        TABLE 148 ROE: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 149 ROE: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 150 ROE: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 151 ROE: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 152 ROE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
                        FIGURE 34 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035
                        FIGURE 35 ASIA PACIFIC: CANCER BIOMARKERS MARKET SNAPSHOT
                        TABLE 153 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY COUNTRY, 2020–2026 (USD MILLION)
                        TABLE 154 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY CANCER TYPE, 2020–2026 (USD MILLION)
                        TABLE 155 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
                        TABLE 156 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
                        TABLE 157 ASIA PACIFIC: OMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 158 ASIA PACIFIC: GENOMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 159 ASIA PACIFIC: IMAGING TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 160 ASIA PACIFIC: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 161 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY APPLICATION, 2020–2026 (USD MILLION)
             10.3.7 CHINA
                        10.3.7.1 Increasing burden of diseases and growing focus on novel drugs development to drive demand for cancer biomarkers
                                     TABLE 162 CHINA: CANCER INCIDENCE BY TYPE OF CANCER, 2020 VS. 2040
                                     TABLE 163 CHINA: CANCER BIOMARKERS MARKET BY CANCER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 164 CHINA: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 165 CHINA: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
                                     TABLE 166 CHINA: OMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 167 CHINA: GENOMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 168 CHINA: IMAGING TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 169 CHINA: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 170 CHINA: CANCER BIOMARKERS MARKET BY APPLICATION, 2020–2026 (USD MILLION)
             10.3.8 JAPAN
                        10.3.8.1 Strategic collaborations with leading pharmaceutical companies to drive market growth
                                     TABLE 171 JAPAN: CANCER INCIDENCE BY TYPE OF CANCER, 2020 VS. 2040
                                     TABLE 172 JAPAN: CANCER BIOMARKERS MARKET BY CANCER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 173 JAPAN: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 174 JAPAN: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
                                     TABLE 175 JAPAN: OMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 176 JAPAN: GENOMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 177 JAPAN: IMAGING TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 178 JAPAN: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 179 JAPAN: CANCER BIOMARKERS MARKET BY APPLICATION, 2020–2026 (USD MILLION)
             10.3.9 INDIA
                        10.3.9.1 Increased demand for early cancer diagnosis to support market growth
                                     TABLE 180 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                     TABLE 181 INDIA: CANCER BIOMARKERS MARKET BY CANCER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 182 INDIA: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
                                     TABLE 183 INDIA: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
                                     TABLE 184 INDIA: OMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 185 INDIA: GENOMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 186 INDIA: IMAGING TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 187 INDIA: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 188 INDIA: CANCER BIOMARKERS MARKET BY APPLICATION, 2020–2026 (USD MILLION)
             10.3.10 REST OF ASIA PACIFIC
                        TABLE 189 ROAPAC: CANCER BIOMARKERS MARKET BY CANCER TYPE, 2020–2026 (USD MILLION)
                        TABLE 190 ROAPAC: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
                        TABLE 191 ROAPAC: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
                        TABLE 192 ROAPAC: OMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 193 ROAPAC: GENOMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 194 ROAPAC: IMAGING TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 195 ROAPAC: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 196 ROAPAC: CANCER BIOMARKERS MARKET BY APPLICATION, 2020–2026 (USD MILLION)
     10.4 LATIN AMERICA
             10.4.1 GROWING CANCER RESEARCH AND MANUFACTURING ACTIVITIES TO SUPPORT MARKET GROWTH
                        TABLE 197 LATIN AMERICA: CANCER INCIDENCE BY TYPE OF CANCER, 2020 VS. 2040
                        TABLE 198 LATIN AMERICA: CANCER BIOMARKERS MARKET BY CANCER TYPE, 2020–2026 (USD MILLION)
                        TABLE 199 LATIN AMERICA: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
                        TABLE 200 LATIN AMERICA: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
                        TABLE 201 LATIN AMERICA: OMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 202 LATIN AMERICA: GENOMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 203 LATIN AMERICA: IMAGING TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 204 LATIN AMERICA: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 205 LATIN AMERICA: CYTOGENETICS MARKET BY APPLICATION, 2020–2026 (USD MILLION)
     10.5 MIDDLE EAST & AFRICA
             10.5.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET GROWTH
                        TABLE 206 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET BY CANCER TYPE, 2020–2026 (USD MILLION)
                        TABLE 207 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
                        TABLE 208 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
                        TABLE 209 MIDDLE EAST & AFRICA: OMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 210 MIDDLE EAST & AFRICA: GENOMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 211 MIDDLE EAST & AFRICA: IMAGING TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 212 MIDDLE EAST & AFRICA: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION)
                        TABLE 213 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET BY APPLICATION, 2020–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 223)
     11.1 OVERVIEW
     11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
             11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE CANCER BIOMARKERS MARKET
                        TABLE 214 STRATEGIES ADOPTED BY KEY MANUFACTURING COMPANIES
     11.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
             FIGURE 36 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE CANCER BIOMARKERS MARKET
     11.4 MARKET SHARE ANALYSIS
             TABLE 215 CANCER BIOMARKERS MARKET: DEGREE OF COMPETITION
     11.5 COMPANY EVALUATION QUADRANT
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 38 CANCER BIOMARKERS MARKET: COMPANY EVALUATION QUADRANT, 2020
     11.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2020)
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
                        FIGURE 39 CANCER BIOMARKERS MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2020
     11.7 COMPETITIVE BENCHMARKING
             FIGURE 40 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE CANCER BIOMARKERS MARKET
             TABLE 216 COMPANY PRODUCT FOOTPRINT
             TABLE 217 COMPANY REGIONAL FOOTPRINT
     11.8 COMPETITIVE SCENARIO
             11.8.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 218 KEY PRODUCT LAUNCHES & APPROVALS
             11.8.2 DEALS
                        TABLE 219 DEALS

12 COMPANY PROFILES (Page No. - 234)
     12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))* 
             12.1.1 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 220 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
                        FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
             12.1.2 THERMO FISHER SCIENTIFIC INC.
                        TABLE 221 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                        FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020)
             12.1.3 QIAGEN N.V.
                        TABLE 222 QIAGEN N.V.: BUSINESS OVERVIEW
                        FIGURE 43 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
             12.1.4 ILLUMINA, INC.
                        TABLE 223 ILLUMINA, INC.: BUSINESS OVERVIEW
                        FIGURE 44 ILLUMINA, INC.: COMPANY SNAPSHOT
             12.1.5 BIO-RAD LABORATORIES, INC.
                        TABLE 224 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 45 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
             12.1.6 ABBOTT LABORATORIES
                        TABLE 225 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 46 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
             12.1.7 BIOMΙRIEUX SA
                        TABLE 226 BIOMΙRIEUX SA: BUSINESS OVERVIEW
                        FIGURE 47 BIOMΙRIEUX SA: COMPANY SNAPSHOT
             12.1.8 BECTON DICKINSON AND COMPANY
                        TABLE 227 BECTON DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
             12.1.9 MERCK MILLIPORE
                        TABLE 228 MERCK MILLIPORE: BUSINESS OVERVIEW
                        FIGURE 49 MERCK MILLIPORE: COMPANY SNAPSHOT
             12.1.10 AGILENT TECHNOLOGIES
                        TABLE 229 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW
                        FIGURE 50 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2021)
     12.2 OTHER PLAYERS
             12.2.1 MYRIAD GENETICS, INC.
             12.2.2 SYSMEX CORPORATION
             12.2.3 HOLOGIC, INC.
             12.2.4 QUEST DIAGNOSTICS
             12.2.5 CENTOGENE N.V.
             12.2.6 PERKINELMER, INC.
             12.2.7 SIEMENS HEALTHINEERS
             12.2.8 EXACT SCIENCES
             12.2.9 R&D SYSTEMS, INC.
             12.2.10 BIOVISION INC.
             12.2.11 OLINK
             12.2.12 ASURAGEN, INC.
             12.2.13 MESO SCALE DIAGNOSTICS, LLC
             12.2.14 INVIVOSCRIBE, INC.
             12.2.15 SEEGENE TECHNOLOGIES, INC.
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies. 

13 APPENDIX (Page No. - 280)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the cancer biomarkers market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.

The Following is a Breakdown of the Primary Respondents:

Cancer Biomarkers Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the cancer biomarkers market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the cancer biomarkers market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Global Cancer Biomarkers Market Size: Top-Down Approach

Cancer Biomarkers Market Size, and Top-Down Approach

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, segment, and forecast the cancer biomarkers market by biomarkers type, cancer type, profiling technologies, application, and region.
  • To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and challenges).
  • To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market.
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa,
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2.
  • To track and analyze company developments such as product launches, regulatory approvals, partnerships, collaboration, and acquisitions in the cancer biomarkers market.
  • To benchmark players within the market using the proprietary “Competitive Leadership Mapping” framework, which analyzes market players on various parameters within the broad categories of business and product strategy.

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

  • Cancer biomarkers market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa.

Company profiles

  • Product portfolio matrix for leading market players.
Report Code
MD 5627
Published ON
Mar, 2022
Choose License Type
BUY NOW
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Cancer Biomarkers Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved